We are live on
!
Find out more
AAP
Arax Advisory Partners Portfolio holdings
AUM
$15.1B
1-Year Est. Return
27.93%
This Fund
S&P 500
This Quarter
Est. Return
+16%
1 Year Est. Return
+27.93%
3 Year Est. Return
+64.69%
5 Year Est. Return
+64.07%
10 Year Est. Return
–
AUM
$15.1B
AUM Growth
+$11.5B
(+326%)
Cap. Flow
+$10.9B
Cap. Flow
% of AUM
71.99%
Top 10 Holdings %
Top 10 Hldgs %
18.25%
Holding
5,282
New
1,517
Increased
3,296
Reduced
222
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$331M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$324M |
| 3 |
NVIDIA
NVDA
|
+$260M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$219M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$172M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HIMU
iShares High Yield Muni Active ETF
HIMU
|
+$4.53M |
| 2 |
Vanguard Morningstar Small-Cap Value ETF
VBR
|
+$3.23M |
| 3 |
Dimensional Emerging Markets Core Equity 2 ETF
DFEM
|
+$2.25M |
| 4 |
Vanguard Morningstar Mid-Cap Value ETF
VOE
|
+$2.21M |
| 5 |
Capital Group Growth ETF
CGGR
|
+$1.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 51.68% |
| 2 | Technology | 13.1% |
| 3 | Industrials | 6.81% |
| 4 | Financials | 6.59% |
| 5 | Energy | 4.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3401
4D Molecular Therapeutics
FDMT
$810M
| $42.9K | ﹤0.01% |
3,227
+2,959
| +1,104% | +$28.8K |
|
|
GOLD
3402
Gold.com Inc
GOLD
$1.32B
| $42.9K | ﹤0.01% |
1,030
+1,022
| +12,775% | +$44K |
|
3403
Denali Therapeutics
DNLI
$3.84B
| $42.7K | ﹤0.01% |
1,661
+1,360
| +452% | +$27.9K |
|
|
QXO
3404
QXO Inc
QXO
$14B
| $42.6K | ﹤0.01% |
2,468
+1,254
| +103% | +$23.3K |
|
|
TTEQ
3405
T. Rowe Price Technology ETF
TTEQ
$410M
| $42.6K | ﹤0.01% |
956
| – | – |
|
3406
BrightView Holdings
BV
$1.04B
| $42.6K | ﹤0.01% |
3,005
+2,291
| +321% | +$28.7K |
|
3407
Green Plains
GPRE
$1.03B
| $42.5K | ﹤0.01% |
2,766
+1,832
| +196% | +$29.1K |
|
3408
Heartland Express
HTLD
$942M
| $42.4K | ﹤0.01% |
2,784
+2,492
| +853% | +$33.8K |
|
3409
Enovix
ENVX
$737M
| $42.3K | ﹤0.01% |
6,964
+2,425
| +53% | +$16.1K |
|
3410
Energy Recovery
ERII
$397M
| $42.2K | ﹤0.01% |
+4,683
| New | +$44.5K |
|
3411
Butterfly Network
BFLY
$2.24B
| $42.2K | ﹤0.01% |
+5,010
| New | +$25.9K |
|
3412
Ormat Technologies
ORA
$6.34B
| $42.1K | ﹤0.01% |
+387
| New | +$48K |
|
|
GROZ
3413
Zacks Focus Growth ETF
GROZ
$112M
| $42.1K | ﹤0.01% |
1,324
| – | – |
|
|
RNA
3414
Atrium Therapeutics
RNA
$233M
| $42.1K | ﹤0.01% |
+3,128
| New | +$40.9K |
|
3415
Hyster-Yale Materials Handling
HY
$609M
| $42K | ﹤0.01% |
1,198
+1,086
| +970% | +$39.5K |
|
3416
National Beverage
FIZZ
$3.05B
| $42K | ﹤0.01% |
1,346
+988
| +276% | +$34.4K |
|
3417
Evolent Health
EVH
$520M
| $41.8K | ﹤0.01% |
7,720
+7,714
| +128,567% | +$29.6K |
|
3418
Dr. Reddy's Laboratories
RDY
$10.1B
| $41.8K | ﹤0.01% |
2,883
-345
| -11% | -$4.65K |
|
3419
CareDx
CDNA
$2.58B
| $41.8K | ﹤0.01% |
1,465
+980
| +202% | +$21.3K |
|
3420
CTS Corp
CTS
$1.62B
| $41.7K | ﹤0.01% |
640
+615
| +2,460% | +$36.9K |
|
3421
US Physical Therapy
USPH
$1.17B
| $41.6K | ﹤0.01% |
606
-232
| -28% | -$15.8K |
|
3422
Omnicell
OMCL
$1.51B
| $41.5K | ﹤0.01% |
1,000
+906
| +964% | +$36.5K |
|
3423
Helmerich & Payne
HP
$4.25B
| $41.5K | ﹤0.01% |
1,267
+1,091
| +620% | +$40.8K |
|
3424
Invesco S&P 500 Equal Weight Utilities ETF
RSPU
$522M
| $41.4K | ﹤0.01% |
510
| – | – |
|
3425
Ezcorp Inc
EZPW
$2.03B
| $41.3K | ﹤0.01% |
+1,196
| New | +$37.7K |
|
Similar funds
VIM
II
JFG
TWIM
IFP
SAM
WA
NMIFOAC
Arax Advisory Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Arax Advisory Partners held 5,282 positions worth $15.1B, up 326% from $3.54B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Arax Advisory Partners deployed $10.9B of net new capital in Q2 2026, opening 1,517 new positions and adding to 3,296 existing holdings. Its largest new stake was ClearShares Piton Intermediate Fixed Income ETF: 984,286 shares worth $92M.
By sector, the portfolio is most concentrated in Miscellaneous at 52% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was iShares High Yield Muni Active ETF, an estimated $4.53M trimmed.
- Arax Advisory Partners's largest Q2 2026 buy was ClearShares Piton Intermediate Fixed Income ETF: 984,286 shares worth $92M.
- Arax Advisory Partners added most to Apple in Q2 2026, an estimated $331M increase.
- Arax Advisory Partners's biggest Q2 2026 reduction was iShares High Yield Muni Active ETF, cutting an estimated $4.53M.
- Arax Advisory Partners fully exited Monroe Capital Corp in Q2 2026, selling an estimated $379K.
- Arax Advisory Partners's ten largest holdings make up 18% of its $15.1B portfolio in Q2 2026.
- Arax Advisory Partners opened 1,517 new positions and closed 78 in Q2 2026.
- Arax Advisory Partners's portfolio value rose 326% quarter-over-quarter to $15.1B.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.